Dianthus Therapeutics Earnings Review: Q4 Summary
Benzinga Insights 8 months ago
Earnings
Dianthus Therapeutics (NASDAQ:DNTH) announced its Q4 earnings on Monday, March 9, 2026 at 07:09 AM.
Here's a breakdown of the earnings report.
Earnings
Dianthus Therapeutics missed estimated earnings by -41.58%, reporting an EPS of $-1.43 versus an estimate of $-1.01.
Revenue was down $1.04 million from the same period last year.
Analysis of Past Earnings
In the previous quarter, the company missed on EPS by $0.09, resulting in a 8.0% increase change in the share price the following day.
Here's a look at Dianthus Therapeutics's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.88 | -0.86 | -0.71 | -0.85 |
| EPS Actual | -0.97 | -0.88 | -0.82 | -0.81 |
| Revenue Estimate | 578K | 1.01M | 806K | 859K |
| Revenue Actual | 396K | 193K | 1.16M | 1.32M |
Listen to the earnings announcement yourself by clicking here.
To track all earnings releases for Dianthus Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.